<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39366112</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>17</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-2472</ISSN><JournalIssue CitedMedium="Internet"><Volume>243</Volume><PubDate><Year>2024</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Thrombosis research</Title><ISOAbbreviation>Thromb Res</ISOAbbreviation></Journal><ArticleTitle>COVID-19 venous thromboembolism prophylaxis guidelines in pediatrics.</ArticleTitle><Pagination><StartPage>109169</StartPage><MedlinePgn>109169</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.thromres.2024.109169</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0049-3848(24)00301-3</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">SARS-CoV-2 (COVID-19) infection and multisystem inflammatory syndrome in children (MIS-C) are risk factors for venous thromboembolism (VTE). Guidelines for VTE prophylaxis were established at our institution at the beginning of the pandemic. Patients who had any VTE risk factors in addition to COVID-19 met criteria for anticoagulation prophylaxis. Patients who were diagnosed with MIS-C met criteria regardless of additional risk factors.</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">We conducted a retrospective review of patients admitted with COVID-19 or MIS-C to determine compliance with VTE prophylaxis guidelines and to evaluate the incidence of VTE and bleeding events in our population.</AbstractText><AbstractText Label="RESULTS AND CONCLUSIONS" NlmCategory="CONCLUSIONS">Among a total of 678 patients admitted with COVID-19 or MIS-C, 519 (76 %) patients met criteria for VTE prophylaxis and 348 (65.6 %) started prophylaxis. Logistic regression analysis identified a personal or family history of thrombosis or thrombophilia, diagnosis of MIS-C, admission to the intensive care unit, and presence of a central venous catheter as significantly associated with starting VTE prophylaxis. There were 18 patients who developed VTE. Minor bleeding events occurred in 19 patients (5 %), patient important bleeding, no intervention occurred in 8 patients (2 %), clinically relevant nonmajor bleeding in 8 patients (2 %), and major bleeding in 10 patients (3 %). The incidence of VTE in our patients with COVID-19 and MIS-C is similar to VTE rates at other institutions. We found that universally recognized VTE risk factors were appropriate to include as risk factors for thrombosis in hospitalized children with COVID-19 and MIS-C.</AbstractText><CopyrightInformation>Copyright © 2024 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>McElroy</LastName><ForeName>Sara</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Pediatric Hematology and Oncology, Children's Mercy Hospital, University of Missouri-Kansas City School of Medicine, 2401 Gillham Rd., Kansas City, MO 64108, United States of America. Electronic address: smmcelroy@cmh.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cramer</LastName><ForeName>Emily</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Health Services and Outcomes Research, Children's Mercy Hospital, University of Missouri-Kansas City School of Medicine, 2401 Gillham Rd., Kansas City, MO 64108, United States of America. Electronic address: ecramer@cmh.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amos</LastName><ForeName>Lauren</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Pediatric Hematology and Oncology, Children's Mercy Hospital, University of Missouri-Kansas City School of Medicine, 2401 Gillham Rd., Kansas City, MO 64108, United States of America. Electronic address: lamos@cmh.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Thromb Res</MedlineTA><NlmUniqueID>0326377</NlmUniqueID><ISSNLinking>0049-3848</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000925">Anticoagulants</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C000705967">pediatric multisystem inflammatory disease, COVID-19 related</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054556" MajorTopicYN="Y">Venous Thromboembolism</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000925" MajorTopicYN="Y">Anticoagulants</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017410" MajorTopicYN="N">Practice Guidelines as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006470" MajorTopicYN="N">Hemorrhage</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018746" MajorTopicYN="N">Systemic Inflammatory Response Syndrome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Anticoagulation</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">MIS-C</Keyword><Keyword MajorTopicYN="N">Prophylaxis</Keyword><Keyword MajorTopicYN="N">Thrombosis</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Lauren Amos reports a relationship with Sanofi that includes: consulting or advisory and speaking and lecture fees. Lauren Amos reports a relationship with HemaBiologics that includes: consulting or advisory. Lauren Amos reports a relationship with Genentech that includes: consulting or advisory. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>18</Day><Hour>10</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>6</Day><Hour>7</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>4</Day><Hour>18</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39366112</ArticleId><ArticleId IdType="doi">10.1016/j.thromres.2024.109169</ArticleId><ArticleId IdType="pii">S0049-3848(24)00301-3</ArticleId></ArticleIdList></PubmedData></PubmedArticle>